The digital display will indicate when the last dose has been delivered after dose 01, the counter will read 00 and the cap will lock, at which time the unit must be discarded. This helps to reduce the risk of candidiasis. After inhalation, patients are advised to rinse the mouth and spit out the water. The arrow on the cap will be fully aligned with the counter window. To close, while holding the unit in an upright position, replace the cap immediately after each inhalation, loading for the next dose by rotating the cap clockwise while gently pressing down until a click sound is heard and the cap is fully closed. The patient is not to breathe out through the inhaler. Then, the inhaler is removed from the mouth, and the breath held for about 10 seconds, or as long as is comfortable. Instruct the patient to place the inhaler in the mouth, closing the lips around the mouthpiece, and to breathe in rapidly and deeply. The counter will register the number down by one count. The inhaler can be opened by removing the white cap while holding unit upright (the pink-coloured base down), gripping the base, and twisting the cap counterclockwise. Prior to removing the cap, be sure the counter and the pointer on the cap are aligned. Patients should be in an upright position when inhaling the product.
#Metaz alternative how to
The patient needs to be instructed how to use the inhaler correctly (see below).
No data are available.Įlderly patients older than 65 years of age The safety and efficacy of Metaz 200 mcg in children less than 12 years of age have not been established. Severe asthma : continuous symptoms frequent exacerbations frequent night-time asthma symptoms physical activities limited by asthma symptoms PEF or FEV 1≤ 60% predicted, variability > 30% Moderate asthma : symptoms daily exacerbations affect activity and sleep night-time asthma symptoms > 1 time a week daily use of short-acting beta 2 -agonist PEF or FEV 1 > 60- 30 % Mild asthma : symptoms > 1 time a week but 2 times a month PEF or FEV 1 > 80 % predicted, variability 20 - 30 % The patient should be instructed that Metaz 200 micrograms Inhalation Powder is not intended to be used "on demand" as a reliever medication to treat acute symptoms and that this product must be taken regularly to maintain therapeutic benefit even when he or she is asymptomatic. During withdrawal of oral corticosteroids, patients must be carefully monitored for signs of unstable asthma, including objective measures of airway function, and for adrenal insufficiency (see 4.4).
Generally, these decrements are not to exceed 2.5 mg of prednisone daily, or its equivalent.Ī slow rate of withdrawal is strongly recommended. The next reduction is made after an interval of one to two weeks, depending on the response of the patient. After approximately one week, gradual withdrawal of the systemic corticosteroid can be initiated by reducing the daily or alternate daily dose. In patients with severe asthma and previously receiving oral corticosteroids, Metaz 200 micrograms Inhalation Powder will be initiated concurrently with the patient's usual maintenance dose of systemic corticosteroid. When symptoms are controlled, titrate Metaz 200 micrograms Inhalation Powder to the lowest effective dose.
Patients with severe asthma: The recommended starting dose is 400 micrograms twice daily, which is the maximum recommended dose. Dose reduction to 200 micrograms once daily given in the evening may be an effective maintenance dose for some patients. The dose of Metaz 200 micrograms Inhalation Powder should be individualised and titrated to the lowest dose at which effective control of asthma is maintained. Some patients may be more adequately controlled on 400 micrograms daily, given in two divided doses (200 micrograms twice daily). Data suggest that better asthma control is achieved if once daily dosing is administered in the evening. Patients with persistent mild to moderate asthma: The recommended starting dose for most of these patients is 400 micrograms once daily. StatPearls Publishing 2022.Dosage recommendations are based on severity of asthma (see criteria below). Education announcement: use of topical steroids for eczema. Rational and ethical use of topical corticosteroids based on safety and efficacy. Side-effects of topical steroids: A long overdue revisit. Steroids (topical).Ĭoondoo A, Phiske M, Verma S, Lahiri K. StatPearls Publishing.Īmerican Osteopathic College of Dermatology. The topical corticosteroid classification called into question: towards a new approach. Mechanisms of action of topical corticosteroids in psoriasis. Diagnosis of atopic dermatitis: mimics, overlaps, and complications.
0 kommentar(er)
